Literature DB >> 7778301

Analysis of ALV-based packaging cell lines for production of contaminant defective viruses.

A Girod1, F L Cosset, G Verdier, C Ronfort.   

Abstract

We have previously described avian leukosis virus-based packaging cell lines that express gag, pol, and env proteins from two transcomplementing genomes and produce helper-free stocks of retroviral vectors with different host ranges. In this report, we demonstrated that (i) despite the deletion of the psi packaging sequence, the packaging-defective transcomplementing retroviral transcripts were packaged into virions at a level that could reach 2.3% of a wild-type virus packaging level and (ii) despite deletion of the 3' LTR, these genomes were transferred along with the vector to target cells. As these genomes were also bearing a selectable gene, titers of the resulting contaminant particles could be estimated, depending on the cell line to be between 0 and 6 infectious particles/ml of supernatant.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7778301     DOI: 10.1006/viro.1995.1302

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  3 in total

1.  A replication-competent retrovirus arising from a split-function packaging cell line was generated by recombination events between the vector, one of the packaging constructs, and endogenous retroviral sequences.

Authors:  H Chong; W Starkey; R G Vile
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

2.  Homologous and nonhomologous retroviral recombinations are both involved in the transfer by infectious particles of defective avian leukosis virus-derived transcomplementing genomes.

Authors:  A Girod; A Drynda; F L Cosset; G Verdier; C Ronfort
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

3.  High-titer packaging cells producing recombinant retroviruses resistant to human serum.

Authors:  F L Cosset; Y Takeuchi; J L Battini; R A Weiss; M K Collins
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.